Dr Mathew Garnett, a leading figure in precision cancer medicine, has dedicated his career to unravelling the complexities of cancer biology and translating these findings into new cancer treatments. Notable achievements in his early career include contributing to the identification of the BRAF cancer gene, advancing our knowledge of RAF regulation with implications for targeted BRAF cancer drugs. Additionally, he uncovered UBE2S's role in regulating cell division and influencing responses to anti-mitotic cancer drugs. At the forefront of CRISPR gene-editing, Dr Garnett's research has uncovered insights into gene function and targeting the treatment of tumours. A key discovery was the identification of Werner syndrome helicase as a target in cancers with microsatellite instability, leading to the clinical development of WRN inhibitors and new insights into DNA mismatch repair machinery. Dr Garnett's laboratory has pioneered systematic drug and CRISPR screens in genomically-annotated cell models, identifying treatment response biomarkers and new drug targets. These reference datasets have directly contributed to drug discovery programmes and are shared through leading online portals, including the Cell Model Passports and Genomics of Drug Sensitivity hosted by his laboratory, influencing hundreds of publications. He co-leads the Cancer Dependency Map, guiding precision medicines. His team demonstrated the feasibility of creating a Biobank of human tumour organoids and have contributed hundreds of organoid models to the international Human Cancer Model Initiative (HCMI) as a community resource. As a founder of Mosaic Therapeutics, and through industry collaboration, Dr Garnett plays a crucial role in using genomics to develop cancer drugs. Together, Dr Garnett's scientific discoveries are leading to clinical innovations directly informing personalised treatment of cancer.